Regulus Therapeutics Inc. announced the appointments of Rekha Garg, M.D., M.S., to Senior Vice President, Clinical Development and Regulatory, and Claire Padgett, Ph.D. to Senior Vice President, Clinical Operations. The company also announced the promotion of Morgan Carlson, Ph.D., to Vice President, Biology and Edmund Lee, Ph.D., to Vice President, Translational Medicine. Lastly, the Company announced, Denis Drygin, Ph.D., has stepped down from his role as Chief Scientific Officer to pursue other opportunities.

Both Drs. Garg and Padgett have been working with the Company as consultants moving the Phase 1 ADPKD program forward and are happy to welcome them as employees to the Regulus team. Additionally, the promotions of Dr. Lee and Dr. Carlson to the newly created roles of Vice President, Translational Medicine and Vice President, Biology are in recognition of their accomplishments in the development of biomarker strategy for ADPKD program as well as the effective leadership of earlier stage research efforts.

would also like to express gratitude to Denis, thank him for his many contributions and wish him the best in the next phase of his career."Dr. Garg is a physician executive with over 20 years of experience in leadership roles in the biopharma industry, across multiple therapeutic areas including kidney diseases. Before joining Regulus, she was Senior Vice President, Regulatory Affairs and Safety, at Sanifit Therapeutics. Prior to that, she was Vice President at Infinity Pharmaceuticals and served in multiple leadership roles in clinical development focused on regulatory affairs and risk management at Amgen and Eli Lilly.

Prior to joining the pharmaceutical industry, she held a similar role the National Heart, Lung, and Blood Institute. Dr. Garg received her BA in Biology from Oberlin College, her M.D. from the Medical College of Ohio and completed her residency at the University of Maryland School of Medicine where she also received an M.S. in Epidemiology.Dr. Padgett has more than 25 years of experience in clinical and development operations, with experience in these functions accrued at multiple biotech companies including Sanifit Therapeutics, a company focused on the Phase 3 clinical development of SNF472 in chronic kidney disease. Previously she held similar roles at Mirati Therapeutics, Mast Therapeutics, and Cylene Pharmaceuticals.

She earned an MBA from Seton Hall University and holds a Ph.D. in organizational management and leadership from Capella University.Dr. Lee joined Regulus in 2013 from Hoffmann-La Roche and Millennium Pharmaceuticals (now Takeda Oncology), where he participated in the discovery of the proteosome inhibitor ixazomib (MLN9708) for the treatment of multiple myeloma. Edmund has led numerous discovery and translational research programs at Regulus, including most recently the first anti-miR-17 oligonucleotide (RGLS4326), as well as the next-generation anti-miR-17 (RGLS8429) for the potential treatment of ADPKD. Edmund received his Ph.D. in cell and molecular biology from the University of Notre Dame and completed his postdoctoral training at the Fred Hutchinson Cancer Research Center.Dr. Carlson joined Regulus in 2020.

He was previously a senior investigator at Novartis, and before that, an assistant professor of genetics and developmental biology at the University of Connecticut School of Medicine and Stem Cell Institute, where his research laboratory focused on biological aging and tissue regeneration to drive the discovery of novel mechanisms and therapeutics for treating musculoskeletal degenerative disease. Dr. Carlson earned a joint Ph.D. in bioengineering from University of California, San Francisco and Berkeley, and was a postdoctoral research fellow at Children's Hospital of Oakland Research Institute and University of California, Berkeley.